Scarica l'app Stockscreener
0.3358
1.24%
-0.0042
Dopo l'orario di chiusura:
.32
-0.0158
-4.71%
Precedente Chiudi:
$0.34
Aprire:
$0.3382
Volume 24 ore:
552.78K
Relative Volume:
0.05
Capitalizzazione di mercato:
$16.87M
Reddito:
$598.00K
Utile/perdita netta:
$-44.93M
Rapporto P/E:
-0.0404
EPS:
-8.31
Flusso di cassa netto:
$-17.32M
1 W Prestazione:
-11.26%
1M Prestazione:
+0.72%
6M Prestazione:
-80.39%
1 anno Prestazione:
-78.95%
Intervallo 1D:
$0.32
$0.3666
Intervallo di 1 settimana:
$0.312
$0.37
Portata 52W:
$0.2212
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Nome
Eterna Therapeutics Inc
Settore
Industria
Telefono
(212) 582-1199
Indirizzo
1035 CAMBRIDGE STREET, CAMBRIDGE
Confronta ERNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERNA
Eterna Therapeutics Inc
|
0.3358 | 16.87M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eterna Therapeutics Inc Borsa (ERNA) Ultime notizie
ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Eterna Therapeutics expands scientific board with oncology experts - MSN
Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL
Eterna Therapeutics expands scientific board with oncology experts By Investing.com - Investing.com Canada
Eterna Therapeutics Announces Expansion of Scientific Advisory Board - GlobeNewswire
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 1/16/25 - TipRanks
What Did We Note About Insider Trading At Meiwu Technology Company Ltd (NASDAQ: WNW)? - Stocks Register
ERNA-101 extends survival in mice with ovarian cancer - BioWorld Online
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
Wall Street Climbs as Producer Inflation Report Offers Relief to Investors – Market - HPBL
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Eterna Therapeutics reports breakthrough in ovarian cancer treatment - Investing.com
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites - The Manila Times
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer - Yahoo Finance
Eterna Therapeutics faces Nasdaq delisting over market value - Investing.com
Eterna Therapeutics Faces Nasdaq Compliance and Board Changes - TipRanks
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer - The Manila Times
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors - Yahoo Finance
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Growth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion Landscape - GlobeNewswire
Eterna Therapeutics Inc. Announces Appointment of Dr. Elena Ratner to Board of Directors - Marketscreener.com
Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
ERNA stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - The Eastern Progress Online
Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online
Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada
Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire
Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research - StockTitan
ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia
Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa
Eterna Therapeutics Inc Azioni (ERNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):